Press releases

ORYZON strengthens regulatory strategy with the appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs

ORYZON receives feedback from the FDA in response to the submitted Phase III protocol in Borderline Personality Disorder

ORYZON strengthens patent portfolio for iadademstat with European grant decision covering combinations with PD1/PD-L1 inhibitors

ORYZON to participate in upcoming events in September and October

ORYZON to sponsor first Phelan-McDermid syndrome (PMS) burden of illness study

ORYZON strengthens patent portfolio for iadademstat and vafidemstat with new Decisions to Grant

ORYZON Finalist at the 2025 European Lifestars Awards

ORYZON receives European Medicines Agency approval to initiate a Phase Ib study of iadademstat in sickle cell disease

ORYZON reports financial results and corporate update for half-year ending June 30, 2025

Expanding analyst interest in ORYZON